HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP.
Yang G, et al. Among authors: cohen p.
Blood. 2016 Jun 23;127(25):3237-52. doi: 10.1182/blood-2016-01-695098. Epub 2016 May 3.
Blood. 2016.
PMID: 27143257
Free article.